Mission

The Social Pain Institute advances the neuroscience of social pain and expands clinical access to treatments that address its underlying mechanisms — particularly for people with personality disorders and related conditions who have been failed by existing care.

The idea

Social pain — the distress of rejection, exclusion, and lost connection — appears to be processed by much of the same neural circuitry as physical pain, mediated by the endogenous opioid system. Several psychiatric conditions are defined by persistent social difficulty, and those are often the same conditions that lack effective medications. That may not be a coincidence. The social difficulty in these conditions may reflect chronic dysfunction of that system — a physiological problem, not only a psychological one.

If that is right, it points to a different kind of help: treatments that work with the opioid system, investigated seriously rather than dismissed out of hand. Most attention so far has gone to opioid antagonists such as naltrexone, with mixed results. More recently, interest has turned to buprenorphine — a partial agonist with an unusual safety profile — where early studies and clinical reports suggest it may ease suicidality and related symptoms for some people. The evidence is still preliminary: a hypothesis with a growing base, not a settled treatment. Being honest about that distinction guides everything we publish.

Why an organization

The bottleneck is not the idea; it is that no one has been translating it into research, practice, and policy. SPI exists to fill that gap. We cannot run the trials, rewrite the guidelines, or change policy directly — but we can remove the specific barriers that keep those things from happening.

How we create change

We are a field-building organization. Our job is to make the research, the clinical change, and the policy shift more likely by doing the work that sits in front of them:

• Making the case — showing the research is worth doing, through a citation-audited clinical guide, public writing, and direct outreach.
• Connecting people — linking researchers who don’t know each other, researchers who don’t know key clinical observations, and funders who don’t know researchers are interested.
• Reducing friction — documenting patient-recruitment feasibility and synthesizing the literature so a capable team can move faster.
• Creating demand — building the patient and clinician community that shows there is a constituency waiting for this work.
• Advocacy — making the public and professional case for buprenorphine as a legitimate mental-health treatment.

What we’re working toward

Over the long term, we want to see buprenorphine established as an evidence-based option for BPD; people recognized and supported earlier in life, so fewer years are lost before effective help arrives; the research extended to other conditions where opioid-system dysregulation may play a role; and a shift in how buprenorphine is understood — as a legitimate mental-health treatment, not only an addiction or physical pain medicine.

In the nearer term, that means at least one research team moving on a pilot or trial, a clinical guide with real reach among prescribers, and a public conversation that has begun to shift.

If your work touches any of this — research, clinical practice, funding, or press — we’d like to hear from you.